Skip to main content

Advertisement

Table 1 Demographic characteristics of the patient population

From: Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles

  Whole cohort (n = 164) ISG negative (n = 101) ISG positive (n = 63) p value (ISG positive vs. negative)
Age (years) 48.5 (36.8, 57.3) 50.3 (40.6, 59.5) 44.8 (31.6, 52.8) 0.012
Gender, female 155 (94.5) 97 (96.0) 58 (92.1) 0.277
Disease duration (years) n = 158 7.11 (3.16, 15.8) 6.84 (3.06, 15.3) 8.08 (3.56, 16.1) 0.538
Age at disease onset (years) 36.5 (26.2, 47.4) 40.5 (30.1, 48.4) 31.6 (23.6, 41.1) 0.005
Ethnicity
 Caucasian 122 (74.8) 80 (79.2) 42 (66.7) 0.430
 Mixed 1 (0.6) 1 (0.99) 0
 Asian or Asian British 8 (4.9) 3 (2.97) 5 (7.94)
 Black or Black British 24 (14.6) 12 (11.9) 12 (19.0)
 Other 10 (6.1) 4 (3.96) 4 (6.35)
 Unknown 1 1 (0.99) 0
Disease group
 UCTD 43 (26.2) 34 (33.7) 9 (14.3) < 0.0001
 SLE 67 (40.9) 40 (39.6) 27 (42.9)
 MCTD 13 (7.93) 4 (3.96) 9 (14.3)
 SS 20 (12.2) 6 (5.94) 14 (22.2)
 IIM 8 (4.88) 6 (5.94) 2 (3.17)
 SSc 13 (7.93) 11 (10.9) 2 (3.17)
Concomitant medication use
 Oral prednisolone 45 (27.3) 28 (27.7) 17 (27.0) 0.918
 Anti-malarial* 96 (58.5) 64 (63.4) 32 (50.8) 0.112
 Immunosuppressant** 47 (28.7) 28 (27.7) 19 (30.2) 0.737
 Biological agent (within 6 months) 2 (1.22) 2 (1.98) 0 0.261
 Daily dose prednisolone (mg) 7.5 (5.0, 10) 7.5 (5.0, 10) 7.5 (6.25, 10) 0.552
Autoantibodies
 dsDNA 46 (28.0) 24 (23.8) 22 (34.9) 0.122
 Ro/SS-A 49 (29.9) 18 (17.8) 31 (49.2) < 0.0001
 La/SS-B 23 (14.0) 9 (8.91) 14 (22.2) 0.017
 Smith 23 (14.0) 5 (4.95) 18 (28.6) < 0.0001
 RNP 39 (23.8) 13 (12.9) 26 (41.3) < 0.0001
 Chromatin 33 (20.1) 9 (8.91) 24 (38.1) < 0.0001
 Rheumatoid factor 37 (22.6) 12 (11.9) 25 (29.7) < 0.0001
 CCP 7 (4.3) 3 (2.97) 4 (6.35) 0.298
 SSC-specific† 15 (9.1) 11 (10.9) 4 (6.35) 0.326
 Jo-1 4 (2.4) 3 (2.97) 1 (1.59) 0.577
Clinical features
 Photosensitivity 64 (39.3) 43 (42.6) 21/62 (33.9) 0.174
 Myositis-specific rash 10 (6.10) 7 (6.93) 3 (4.76) 0.419
 Discoid lesion 6 (3.68) 3 (2.97) 3/62 (4.84) 0.414
 Mucosal ulcers 63 (38.7) 41 (40.6) 22/62 (35.5) 0.315
 Raynaud’s syndrome 87 (53.4) 55 (54.5) 32/62 (51.6) 0.424
 Inflammatory arthritis 75 (46.0) 42/100 (42.0) 33 (52.4) 0.129
 Renal disease‡ 24 (14.9) 13/99 (13.1) 11/62 (17.7) 0.281
 Neurological disease ‡ 4 (2.44) 2 (1.98) 2 (3.17) 0.498
 Haematological disorder‡ 74 (46.3) 35/99 (35.4) 39/61 (63.9) < 0.0001
  1. Data are shown as the n(%) or median (IQR). ISG = interferon-stimulated gene
  2. *Hydroxychloroquine, mepacrine or chloroquine phosphate
  3. **Azathioprine, methotrexate, mycophenolate mofetil, ciclosporine, tacrolimus
  4. †Anti-Scl70, anti-centromere and anti-RNA-polymerase III
  5. ‡As the per modified 1997 ACR Classification criteria for SLE